Anas Rasool

Anas Rasool

Auto-generated profile, based on publicly available information

Anas Rasool

Department of Medicine Dow University of Health Sciences Karachi Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
SDShaikh Muhammad Daniyal
Shaikh Muhammad Daniyal
NKNaveen Murad Khatoon
Naveen Murad Khatoon
ARAnas Rasool
Anas Rasool
IGIsbah Gul
Isbah Gul
STSabula Tabish
Sabula Tabish
SASomaiya Ahmed
Somaiya Ahmed
Background: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with heart failure (HF) and type 2 diabetes. Their effect in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS), however, remains unclear. This study evaluated whether SGLT2 inhibitors reduce all‐cause mortality and HF hospitalisations after TAVR. Methods: A systematic search of PubMed, ScienceDirect, Cochrane (CENTRAL), Scopus and Embase was performed through April 2025 for studies comparing post‐TAVR outcomes between SGLT2 inhibitor users and non‐users. Outcomes of interest included a composite of all‐cause mortality or heart failure (HF) hospitalisation, along with the individual components of all‐cause mortality and HF hospitalisation. All outcomes were extracted at 1 year. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random‐effects model. Heterogeneity was quantified using I 2 statistics. Analyses were conducted in R (version 4.4.2). Results: Three studies (1 RCT, 2 Observational) comprising 3187 patients met inclusion criteria. SGLT2 inhibitor use was associated with a reduced risk of the composite outcome (HR: 0.75; 95% CI: 0.65, 0.86; p < 0.01). Individually, therapy lowered all‐cause mortality (HR: 0.72; 95% CI: 0.53, 0.96; p = 0.03) and HF hospitalisations (HR: 0.74; 95% CI: 0.61, 0.90; p < 0.01). Conclusion: In patients with severe AS undergoing TAVR, SGLT2 inhibitors were associated with significant reductions in all‐cause mortality and HF hospitalisations. These findings suggest a promising role for SGLT2 inhibitors in improving post‐TAVR outcomes. However, given the limited data, larger randomised clinical trials are necessary to consolidate these findings. Trial Registration: CRD420251132729

8 January 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
RBRahul Balach
Rahul Balach
AKAyan Khalid
Ayan Khalid
ARAnas Rasool
Anas Rasool
AKAamna Kashif
Aamna Kashif
AAAbdullah Ahmad
Abdullah Ahmad
SASomaiya Ahmed
Somaiya Ahmed
Background: Cutaneous warts are common benign lesions caused by human papillomavirus and often resist conventional treatments. Intralesional immunotherapy with measles–mumps–rubella (MMR) vaccine or vitamin D3 has emerged as an alternative, but their comparative efficacy and safety remain unclear. Methods: We conducted a systematic review and meta‐analysis of nine randomized controlled trials (RCTs) including 742 patients comparing intralesional MMR with vitamin D3 for nongenital cutaneous warts. We searched PubMed, Cochrane CENTRAL, and ScienceDirect up to June 2025, and the protocol was registered in PROSPERO (ID: 1128443). Primary outcomes were complete, partial, and no response; secondary outcomes were recurrence and adverse events (erythema, pain, swelling). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Results: Vitamin D3 achieved lower complete clearance than MMR (RR 0.85; 95% CI 0.75–0.96; p = 0.01) and a higher risk of no response (RR 2.40; 95% CI 1.40–4.13; p = 0.002). No significant differences were seen for partial response (RR 1.24; 95% CI 0.94–1.64; p = 0.13; I 2 = 0%), recurrence (RR 2.20; 95% CI 0.73–6.58; p = 0.16), or pain (RR 0.92; 95% CI 0.74–1.14; p = 0.46). Vitamin D3 was linked to more swelling (RR 2.79; 95% CI 1.15–6.75; p = 0.02), while MMR was associated with more erythema (RR 0.60; 95% CI 0.42–0.86; p = 0.006). Conclusions: Intralesional MMR appears to be more effective than vitamin D3 for cutaneous warts, with superior clearance and distinct adverse event profiles. Larger, standardized trials are warranted to validate these effect sizes and optimize treatment strategies.

10 December 2025 in JGH Open
Verified
Journal Article
Open access
AKAyan Khalid
Ayan Khalid
STSabula Tabish
Sabula Tabish
MBMuhammad Burhan
Muhammad Burhan
MSMuhammad Saad
Muhammad Saad
IGIsbah Gul
Isbah Gul
IHIbrahim Nagmeldin Hassan
Ibrahim Nagmeldin Hassan
Rising antibiotic resistance has challenged empirical regimens for Helicobacter pylori eradication. While concomitant therapy is widely used, its effectiveness is reduced in resistant settings. Tailored therapy, guided by antimicrobial susceptibility testing, may improve outcomes. We performed a meta‐analysis of randomized controlled trials (RCTs) comparing tailored versus concomitant therapy as a first‐line treatment. We searched PubMed, Google Scholar, Cochrane, and ClinicalTrials.gov through April 2025 for RCTs enrolling treatment‐naïve adults with confirmed H. pylori infection. The primary outcome was the eradication rate by intention‐to‐treat (ITT) and per‐protocol (PP) analyses, with adverse events as a secondary outcome. We included eight RCTs with 2524 patients (1332 tailored, 1192 concomitant). Tailored therapy achieved higher eradication rates than concomitant therapy in the ITT analysis (87.4% vs. 83.2%; RR = 1.05; 95% CI: 1.00–1.10; p = 0.05) and the PP analysis (92.6% vs. 89.1%; RR = 1.04; 95% CI: 1.00–1.07; p = 0.03). Furthermore, tailored therapy was associated with a significantly lower incidence of adverse events (35.6% vs. 45.6%; RR = 0.71; 95% CI: 0.58–0.86; p = 0.0007). In conclusion, tailored therapy provides modestly higher H. pylori eradication rates and significantly fewer adverse events compared to empirical concomitant therapy. These findings support using tailored therapy as the preferred first‐line option, particularly in regions with high antibiotic resistance and as access to rapid molecular testing expands.

1 March 2026
Verified
Journal Article
Open access
SDShaikh Muhammad Daniyal
Shaikh Muhammad Daniyal
NKNaveen Murad Khatoon
Naveen Murad Khatoon
ARAnas Rasool
Anas Rasool
IGIsbah Gul
Isbah Gul
STSabula Tabish
Sabula Tabish
SASomaiya Ahmed
Somaiya Ahmed
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with heart failure (HF) and type 2 diabetes. Their effect in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS), however, remains unclear. This study evaluated whether SGLT2 inhibitors reduce all-cause mortality and HF hospitalisations after TAVR. A systematic search of PubMed, ScienceDirect, Cochrane (CENTRAL), Scopus and Embase was performed through April 2025 for studies comparing post-TAVR outcomes between SGLT2 inhibitor users and non-users. Outcomes of interest included a composite of all-cause mortality or heart failure (HF) hospitalisation, along with the individual components of all-cause mortality and HF hospitalisation. All outcomes were extracted at 1 year. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was quantified using I2 statistics. Analyses were conducted in R (version 4.4.2). Three studies (1 RCT, 2 Observational) comprising 3187 patients met inclusion criteria. SGLT2 inhibitor use was associated with a reduced risk of the composite outcome (HR: 0.75; 95% CI: 0.65, 0.86; p < 0.01). Individually, therapy lowered all-cause mortality (HR: 0.72; 95% CI: 0.53, 0.96; p = 0.03) and HF hospitalisations (HR: 0.74; 95% CI: 0.61, 0.90; p < 0.01). In patients with severe AS undergoing TAVR, SGLT2 inhibitors were associated with significant reductions in all-cause mortality and HF hospitalisations. These findings suggest a promising role for SGLT2 inhibitors in improving post-TAVR outcomes. However, given the limited data, larger randomised clinical trials are necessary to consolidate these findings. CRD420251132729.